

COPY OF PAPERS
ORIGINALLY FILED

Attorney Docket No.: 6258.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
APR 24 2002
TECH CENTER 1600/2900

In re Application of: Lau et al

Application No.: 09/996,023

Group Art Unit: To be assigned

Filed: November 16, 2001

Examiner: To be assigned

For: Glucagon Antagonists/Inverse Agonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 00/39088


2. WO 94/14426
3. WO 98/04528
4. WO 98/21957
5. WO 98/22108
6. WO 98/22109
7. WO 99/01423
8. WO 97/16422
9. WO 98/24780
10. WO 98/24782
11. WO 99/24404
12. WO 99/32448
13. US 5,880,139
14. US 5,776,954
15. US 4,359,474
16. US 4,374,130
17. US 5,837,719
18. C.L. Brand et al., "Immunoneutralization of endogenous glucagons with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats" *Diabetologia* Vol. 37 pgs. 985-993 (1994)
19. C.L. Brand et al., "Evidence for a Major Role of Glucagon in the Hyperglycemia of Experimental Diabetes" [535] *Diabetes* 43, [suppl 1], 172A (1994)
20. C. L. Brand et al., *Am. J. Physiol.* 269, E469-E477 (1995)
21. C.L. Brand et al., "Regulation of Insulin and Glucagon Secretion by Glucagon" [492], *Diabetes* 44 [suppl 1], 134A (1995)
22. C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits"., *Diabetes* Vol. 45., pages. 1076-1083 (1996)
23. L.J.Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" *Science* Vol. 259., pages. 1614-1616 (1993)
24. J.L. Collins et al., "CP-99, 711: A NON-PEPTIDE GLUCAGON RECEPTOR ANTAGONIST" *Bioorganic & Med. Chem. Ltr.* Vol. 2, No. 9 pages. 915-918 (1992)
25. P. Madsen et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists" *J. Med. Chem* Vol. 41, pages. 5150-5157 (1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,


Date: January 10, 2002


Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6258.200-US

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

APR 2 12 00 PM '02

RECEIVED 01 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Serial No.: 09/996,023

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 2060

For: Glucagon Antagonists/Inverse Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (25 Total)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on January 10, 2002.

Sylvia Gonzalez

(name of person mailing paper)


(signature of person mailing paper)